tetano
Editor, Senior Moderator
Thromb Res
. 2020 Jun 5;193:110-115.
doi: 10.1016/j.thromres.2020.06.008. Online ahead of print.
Mechanisms Involved in the Development of Thrombocytopenia in Patients With COVID-19
Yujiao Zhang[SUP] 1 [/SUP], Xiaoyuan Zeng[SUP] 1 [/SUP], Yingying Jiao[SUP] 1 [/SUP], Zongpeng Li[SUP] 1 [/SUP], Qifa Liu[SUP] 1 [/SUP], Mo Yang[SUP] 2 [/SUP], Jieyu Ye[SUP] 3 [/SUP]
Affiliations
Abstract
Corona Virus Disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2. Emerging genetic and clinical evidence suggests similarities between COVID-19 patients and those with severe acute respiratory syndrome and Middle East respiratory syndrome. Hematological changes such as lymphopenia and thrombocytopenia are not rare in COVID-19 patients, and a smaller population of these patients had leukopenia. Thrombocytopenia was detected in 5-41.7% of the patients with COVID-19. Analyzing the dynamic decrease in platelet counts may be useful in the prognosis of patients with COVID-19. However, the mechanisms underlying the development of thrombocytopenia remain to be elucidated. This review summarizes the hematological changes in patients infected with SARS-CoV-2 and possible underlying mechanisms of thrombocytopenia development.
Keywords: COVID-19; SARS-CoV-2; Thrombocytopenia.
. 2020 Jun 5;193:110-115.
doi: 10.1016/j.thromres.2020.06.008. Online ahead of print.
Mechanisms Involved in the Development of Thrombocytopenia in Patients With COVID-19
Yujiao Zhang[SUP] 1 [/SUP], Xiaoyuan Zeng[SUP] 1 [/SUP], Yingying Jiao[SUP] 1 [/SUP], Zongpeng Li[SUP] 1 [/SUP], Qifa Liu[SUP] 1 [/SUP], Mo Yang[SUP] 2 [/SUP], Jieyu Ye[SUP] 3 [/SUP]
Affiliations
- PMID: 32535232
- PMCID: PMC7274097
- DOI: 10.1016/j.thromres.2020.06.008
Abstract
Corona Virus Disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2. Emerging genetic and clinical evidence suggests similarities between COVID-19 patients and those with severe acute respiratory syndrome and Middle East respiratory syndrome. Hematological changes such as lymphopenia and thrombocytopenia are not rare in COVID-19 patients, and a smaller population of these patients had leukopenia. Thrombocytopenia was detected in 5-41.7% of the patients with COVID-19. Analyzing the dynamic decrease in platelet counts may be useful in the prognosis of patients with COVID-19. However, the mechanisms underlying the development of thrombocytopenia remain to be elucidated. This review summarizes the hematological changes in patients infected with SARS-CoV-2 and possible underlying mechanisms of thrombocytopenia development.
Keywords: COVID-19; SARS-CoV-2; Thrombocytopenia.